Published in Nature on July 17, 1997
Prions. Proc Natl Acad Sci U S A (1998) 27.80
The most infectious prion protein particles. Nature (2005) 5.37
Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem (2009) 2.80
Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely by environmental exposure. PLoS One (2009) 1.90
Chronic wasting disease and potential transmission to humans. Emerg Infect Dis (2004) 1.87
Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A (1998) 1.80
Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79
Bank Vole Prion Protein As an Apparently Universal Substrate for RT-QuIC-Based Detection and Discrimination of Prion Strains. PLoS Pathog (2015) 1.74
Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A (2000) 1.73
Epidemiological determinants of the pattern and magnitude of the vCJD epidemic in Great Britain. Proc Biol Sci (1998) 1.64
Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J (1999) 1.64
Susceptibility of sheep for scrapie as assessed by in vitro conversion of nine naturally occurring variants of PrP. J Virol (2000) 1.52
Cellular biology of prion diseases. Clin Microbiol Rev (1999) 1.48
Transmission and adaptation of chronic wasting disease to hamsters and transgenic mice: evidence for strains. J Virol (2007) 1.46
Transmission of prions. Proc Natl Acad Sci U S A (2002) 1.36
Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J Virol (2003) 1.35
Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem (2009) 1.29
Prion protein amino acid determinants of differential susceptibility and molecular feature of prion strains in mice and voles. PLoS Pathog (2008) 1.21
Glycosylation influences cross-species formation of protease-resistant prion protein. EMBO J (2001) 1.17
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
Cells expressing anchorless prion protein are resistant to scrapie infection. J Virol (2009) 1.07
Prion protein misfolding and disease. Curr Opin Struct Biol (2009) 1.06
Human prion disease and relative risk associated with chronic wasting disease. Emerg Infect Dis (2006) 1.02
Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid residue 155. J Virol (2001) 1.00
Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. J Virol (2001) 0.98
Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog (2014) 0.97
BSE in Northern Ireland: epidemiological patterns past, present and future. Proc Biol Sci (1998) 0.92
Assessment of the genetic susceptibility of sheep to scrapie by protein misfolding cyclic amplification and comparison with experimental scrapie transmission studies. J Virol (2011) 0.90
Molecular barriers to zoonotic transmission of prions. Emerg Infect Dis (2014) 0.90
Mapping of possible prion protein self-interaction domains using peptide arrays. BMC Biochem (2007) 0.89
Enhanced virulence of sheep-passaged bovine spongiform encephalopathy agent is revealed by decreased polymorphism barriers in prion protein conversion studies. J Virol (2013) 0.82
Seeded fibrillation as molecular basis of the species barrier in human prion diseases. PLoS One (2013) 0.82
The glycosylation status of PrPC is a key factor in determining transmissible spongiform encephalopathy transmission between species. J Virol (2015) 0.81
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Transmission of scrapie prions to primate after an extended silent incubation period. Sci Rep (2015) 0.80
vCJD: the epidemic that never was. New variant Creutzfeldt-Jakob disease: the critique that never was. BMJ (2002) 0.80
Insights into Chronic Wasting Disease and Bovine Spongiform Encephalopathy Species Barriers by Use of Real-Time Conversion. J Virol (2015) 0.80
Molecular interactions between prions as seeds and recombinant prion proteins as substrates resemble the biological interspecies barrier in vitro. PLoS One (2010) 0.78
Prion Type-Dependent Deposition of PRNP Allelic Products in Heterozygous Sheep. J Virol (2015) 0.78
Oral infection by the bovine spongiform encephalopathy prion. Proc Natl Acad Sci U S A (1999) 0.78
Comparison of cattle and sheep colonic permeabilities to horseradish peroxidase and hamster scrapie prion protein in vitro. Gut (1999) 0.78
Spongiform encephalopathies. Tracking turncoat prion proteins. Nature (1997) 0.77
Molecular modeling of prion transmission to humans. Viruses (2014) 0.75
Recent developments in the pathogenesis, diagnosis, and therapy of prion diseases. Dialogues Clin Neurosci (2001) 0.75
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 15.73
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature (1996) 14.40
Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell (1993) 10.15
Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem (1997) 7.62
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 7.26
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol (1987) 7.05
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol (1999) 6.98
Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science (1996) 6.71
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry (1996) 6.47
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med (1998) 5.49
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain (2009) 5.03
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet (2004) 4.85
Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol (2001) 4.80
Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol (2000) 4.76
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet (1997) 4.28
Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22
Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol (1997) 4.16
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science (1992) 3.93
"Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet (1992) 3.74
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 3.62
129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol (1995) 3.60
Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci U S A (1999) 3.54
Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol (1995) 3.44
Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A (1999) 3.43
Geographical distribution of variant CJD in the UK (excluding Northern Ireland). Lancet (1999) 3.39
Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol (2006) 3.29
Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology (2000) 3.23
Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem (1995) 3.20
Identification and characterization of the cps locus of Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infect Immun (1999) 3.14
Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation (1983) 3.09
Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol (1997) 3.05
Predicting the CJD epidemic in humans. Nature (1997) 3.04
Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 3.03
Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome. Exp Neurol (1989) 3.00
Creutzfeldt-Jakob disease and blood transfusion. Lancet (1993) 2.97
Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 2.96
Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry (1990) 2.93
The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet (2000) 2.92
Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry (1999) 2.87
Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc Natl Acad Sci U S A (1985) 2.86
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med (1996) 2.71
A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: Clinical features. J Neurol Neurosurg Psychiatry (1984) 2.68
A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A (1993) 2.63
PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J Gen Virol (1994) 2.63
Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis (2001) 2.62
Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med (1985) 2.59
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Identification of five allelic variants of the sheep PrP gene and their association with natural scrapie. J Gen Virol (1995) 2.55
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain (2006) 2.54
Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion (2000) 2.52
Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A (1999) 2.51
Evaluation of a nurse-run hypertension clinic in general practice. Practitioner (1988) 2.49
Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol (2000) 2.47
Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A (2000) 2.46
FLP-mediated DNA mobilization to specific target sites in Drosophila chromosomes. Nucleic Acids Res (1997) 2.46
Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
BSE transmission to macaques. Nature (1996) 2.32
The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry (2010) 2.29
Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry. Br J Haematol (1999) 2.29
Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms. Cancer (1980) 2.26
Mice with gene targetted prion protein alterations show that Prnp, Sinc and Prni are congruent. Nat Genet (1998) 2.23
PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration (1994) 2.21
Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry (1992) 2.16
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15
Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (1982) 2.15
Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain (2001) 2.14
Natural scrapie in a closed flock of Cheviot sheep occurs only in specific PrP genotypes. Arch Virol (1996) 2.14
Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.11
A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med (1998) 2.08
The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Ann Neurol (1989) 2.07
Deaths from variant Creutzfeldt-Jakob disease. Lancet (1999) 2.04
Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci U S A (1988) 2.04
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
A novel phenotype in familial Creutzfeldt-Jakob disease: prion protein gene E200K mutation coupled with valine at codon 129 and type 2 protease-resistant prion protein. Ann Neurol (1999) 1.98
Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet (2001) 1.97
Transmission of bovine spongiform encephalopathy to sheep and goats. Vet Rec (1993) 1.97
Presenilin-1 mutations in Alzheimer's disease. Nature (2000) 1.97
A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J (1999) 1.96
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain (2004) 1.96